key: cord-0717471-ijo2rx35
authors: Hicks, Emily G.; Kandel, Sylvie E.; Lampe, Jed N.
title: Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M(pro)) inhibitors
date: 2022-04-12
journal: Bioorg Med Chem Lett
DOI: 10.1016/j.bmcl.2022.128732
sha: ef5ca01a6c5a75d939501afdc7e26621aaf85510
doc_id: 717471
cord_uid: ijo2rx35

In the past two years, the COVID-19 pandemic has caused over 5 million deaths and 250 million infections worldwide. Despite successful vaccination efforts and emergency approval of small molecule therapies, a diverse range of antivirals is still needed to combat the inevitable resistance that will arise from new SARS-CoV-2 variants. The main protease of SARS-CoV-2 (M(pro)) is an attractive drug target due to the clinical success of protease inhibitors against other viruses, such as HIV and HCV. However, in order to combat resistance, various chemical scaffolds need to be identified that have the potential to be developed into potent inhibitors. To this end, we screened a high-content protease inhibitor library against M(pro)in vitro, in order to identify structurally diverse compounds that could be further developed into antiviral leads. Our high-content screening efforts retrieved 27 hits each with >50% inhibition in our M(pro) FRET assay. Of these, four of the top inhibitor compounds were chosen for follow-up due to their potency and drugability (Lipinski’s rules of five criteria): anacardic acid, aloesin, aloeresin D, and TCID. Further analysis via dose response curves revealed IC(50) values of 6.8 μM, 38.9 μM, 125.3 μM, and 138.0 μM for each compound, respectively. Molecular docking studies demonstrated that the four inhibitors bound at the catalytic active site of M(pro) with varying binding energies (-7.5 to -5.6 kcal/mol). Furthermore, M(pro) FRET assay kinetic studies demonstrated that M(pro) catalysis is better represented by a sigmoidal Hill model than the standard Michaelis-Menten hyperbola, indicating substantial cooperativity of the active enzyme dimer. This result suggests that the dimerization interface could be an attractive target for allosteric inhibitors. In conclusion, we identified two closely-related natural product compounds from the Aloe plant (aloesin and aloeresin D) that may serve as novel scaffolds for M(pro) inhibitor design and additionally confirmed the strongly cooperative kinetics of M(pro) proteolysis. These results further advance our knowledge of structure-function relationships in M(pro) and offer new molecular scaffolds for inhibitor design.

In the past two years, the COVID-19 pandemic has caused over 5 million deaths and 250 million infections worldwide. Despite successful vaccination efforts and emergency approval of small molecule therapies, a diverse range of antivirals is still needed to combat the inevitable resistance that will arise from new SARS-CoV-2 variants. The main protease of SARS-CoV-2 (M pro ) is an attractive drug target due to the clinical success of protease inhibitors against other viruses, such as HIV and HCV. However, in order to combat resistance, various chemical scaffolds need to be identified that have the potential to be developed into potent inhibitors. To this end, we screened a high-content protease inhibitor library against M pro in vitro, in order to identify structurally diverse compounds that could be further developed into antiviral leads. Our high-content screening efforts retrieved 27 hits each with >50% inhibition in our M pro FRET assay. Of these, four of the top inhibitor compounds were chosen for follow-up due to their potency and drugability (Lipinski's rules of five criteria): anacardic acid, aloesin, aloeresin D, and TCID. Furthermore, M pro FRET assay kinetic studies demonstrated that M pro catalysis is better represented by a sigmoidal Hill model than the standard Michaelis-Menten hyperbola, indicating substantial cooperativity of the active enzyme dimer. This result suggests that the dimerization interface could be an attractive target for allosteric inhibitors. In conclusion, we identified two closely-related natural product compounds from the Aloe plant (aloesin and aloeresin D) that may serve as novel scaffolds for M pro inhibitor design and additionally confirmed the strongly cooperative kinetics of M pro proteolysis. These results further advance our knowledge of structure-function relationships in M pro and offer new molecular scaffolds for inhibitor design.

The global scourge of the COVID-19 pandemic has enveloped the world for two years, leaving over 5 million dead and 250 million infected in its wake 1, 2 . Despite the emerging success of vaccines, a significant number of people remain unvaccinated, either due to lack of availability 3 or vaccine hesitancy 4, 5 . Furthermore, "breakthrough" infections are becoming more common in the vaccinated with the identification of new variants 6, 7 , leaving few therapeutic options available for life threatening infections 8, 9 . This illustrates the need to develop novel small molecule chemical modalities that can be used both to treat severe SARS-CoV-2 infections and as potential prophylactic agents in high-risk population groups.

While the earliest small molecule therapies targeting SARS-CoV-2 directed their activities towards the RNA polymerase target (e.g., remdesivir and molnupiravir), recent attention has turned to the 3C-like viral main protease (3CL pro or M pro ) as a possible drug target [10] [11] [12] [13] [14] [15] [16] [17] . Viral protease inhibitors have previously demonstrated high clinical efficacy against other viruses, such as HIV (human immunodeficiency virus) 18, 19 and HCV (hepatitis C virus) [20] [21] [22] , making M pro an attractive target for antiviral drug development.

Indeed, Pfizer, Inc. has a first-in-class M pro inhibitor currently in Phase III clinical trials 11 , pointing to M pro inhibition as an effective therapeutic strategy. Despite this, a major liability of viral protease inhibitors is the eventual development of resistance, which necessitates their use as part of combination therapy and also the development of second and third generation compounds. This highlights the need for the identification of new lead structures that may function as M pro inhibitor scaffolds 12, 14, 15 . Since the publication of the SARS-CoV-2 M pro crystal structure 23 , a number of campaigns have been conducted to identify selective M pro inhibitors 11, 12, [14] [15] [16] [23] [24] [25] [26] [27] [28] [29] . While most of these published accounts have exclusively involved computational approaches 16, 25, 26, 30 , several have screened existing small molecule libraries for M pro inhibition in vitro 13, 15, 31 . However, these approaches have led to a number of redundant hits with similar mechanisms of action [32] [33] [34] . In order to forestall eventual viral resistance, chemical diversity is an important consideration in identification of early protease inhibitor leads [35] [36] [37] [38] [39] . Even small chemical libraries that are highly diverse can lead to the identification of inhibitors with unique mechanisms of action [40] [41] [42] . In an attempt to expand the chemical diversity of potential scaffolds for SARS-CoV-2 M pro inhibitor lead design, our approach focused on a high-content protease inhibitor library to filter out redundant molecules and obtain unique pharmacophores that could be further exploited by chemical optimization. Here, we report the identification of novel Aloe-derived natural product scaffolds that have the potential to be further optimized into effective clinical candidates, given their high drug-like qualities (Lipinski's rule of five 43, 44 ) and safety profiles. Additionally, our data confirm that SARS-CoV-2 M pro functions as a cooperative dimer, hinting at the possibility of developing allosteric inhibitors that may target and disrupt the enzyme dimer interface.

In order to screen library compounds for inhibitory activity against M pro in an in vitro system, we cloned, expressed, and purified the M pro viral protein in an E. coli based heterologous expression system 45 . To facilitate production of the native protease, we retained the original viral N-terminal autocatalytic cleavage site (SAVLQ↓SGFRK) and modified the C-terminal sequence with the core amino acids of the HRV (human rhinovirus)-3C protease cleavage site (VTFQ↓GP) to permit removal of the His tag needed for the protein purification (see supporting information, Figure S1 ). This construct resulted in high yields of the native protein (see supporting information, Figure S2 ). To ascertain proteolytic activity, we relied on a FRET (fluorescence resonance energy transfer)-based assay with the peptide substrate Dabcyl-KTSAVLQSGFRKME-Edans-NH 2 , which emits a fluorescent signal at 460 nm when cleaved and excited at 360 nm 46 . Once we evaluated our M pro activity assay for linearity as a function of time and protein concentration (see supporting information, Figure S3 were assessed ( Figure 1A ) and compared via the second order Akaike Information Criterion (AICc) 47 .

The resulting kinetic parameters for the Michaelis-Menten fit were K m = 44.6 ± 8.0 M and V max = 359.6 ± 27.8 pmol/s/nmol M pro , and S 50 = 24.2 ± 2.0 M and V max = 269.6 ± 11.4 pmol/s/nmol M pro for the allosteric sigmoidal fit (see supporting information, Table S1 ). Interestingly, the data best fit to the sigmoidal Hill plot with an R 2 of 0.985 and an AICc correct fit probability of 99.98%. This is dramatically apparent when the data is analyzed by the Eadie-Hofstee transformation ( Figure 1B) . The presence of cooperativity in enzyme activity is readily explainable and somewhat expected as the enzyme is reported to be only active as a dimer [48] [49] [50] . However, while allosteric cooperativity has been demonstrated previously for this enzyme [51] [52] [53] , this is the first time that kinetic data have been quantitatively compared to determine the best model for enzyme activity, i.e. either the Michaelis-Menten or the sigmoidal Hill equations ( Figure 1A , Table S1 ). The clear appearance of allosteric kinetics, as represented in the Eadie-Hofstee plot ( Figure 1B) , indicates that the allosteric dimer interface may also be a promising inhibitor target, as was found to be the case for the SARS-CoV-1 M pro enzyme 50 . minutes. The first 20 minutes were used to calculate the initial velocity, and percent inhibition was calculated from the slope compared to the DMSO control. Background from the FRET substrate was subtracted from all samples. All experiments were performed in triplicate and the presented values represent the mean ± standard deviation. Positive "hits" were defined as any compound that inhibited M pro activity by 50% or more. As can be seen in Figure 2 , 27 compounds fell into this category, indicating an assay hit rate of approximately 11.4%. The structures and percent inhibition are shown in Table 1 , demonstrating the chemical diversity present in the hits obtained from the initial library screening. To assess assay robustness, the Z'-factor was calculated for each screening experiment (see supporting information, Figure S4 ). The resulting Z'-factors were between 0.727 and 0.969, well within the guidelines of 0.5 to 1 for a high-throughput assay. 54 Inherent limitations of the FRET-based assay led to 19 of the initial library compounds (8.1%) being eliminated from the assay screen due to either intrinsic fluorescence from the compounds themselves or issues stemming from inner filter effects. Some of the compounds we identified have been previously reported as SARS-CoV-2 M pro inhibitors (see supporting information, Table S2 ), thereby increasing our confidence in the robustness of our M pro screening assay. Interestingly, a number of the most potent compounds are natural products (e.g., anacardic acid, aloesin, aloeresin D).

A total of 236 protease inhibitors were screened at 100 M against M pro . Hits are defined as compounds with over 50% inhibition, represented by black circles. Compounds with less than 50% inhibition are represented by gray squares. Percent inhibition was calculated against DMSO control. Data points represent the mean of three replicates ± standard deviation (several standard deviations are too small to be discernable).

Aloesin and aloeresin D come from the Aloe plant, including Aloe perryi and A. barbadensis (aka, A. vera) species 55, 56 . These compounds have a long history of medicinal use as stimulant-laxatives to treat constipation 57 , anti-inflammatory compounds to promote wound healing 58 , and bittering agents in food supplements, thereby demonstrating their positive safety profile and bioavailability in humans 56 .

Furthermore, aloesin is a known tyrosinase inhibitor with an IC 50 of 0.9 mM against mushroom tyrosinase 59, 60 . Anacardic acid is a natural product from the cashew nut that exhibits anti-inflammatory and antinociceptive properties. 61 Due to the chemical novelty of the natural products identified and the availability of readily accessible functional groups on these compounds for further modification, we decided to focus on the top three natural products with high percent inhibition in the 100 μM screen:

anacardic acid (96.1% ± 0.1), aloesin (80.1% ± 2.9), and aloeresin D (72.6% ± 1.1). Percent inhibition values represent mean of three replicates ± standard deviation. a Compound with background fluorescence.

We also chose to include the non-natural product TCID (a selective ubiquitin C-terminal hydrolase-L3 inhibitor), due to its performance in the high-content screen (94.2% ± 2.5) 62 . In order to quantitatively assess the extent of M pro inhibition, we performed IC 50 experiments using the screening assay that we had already developed. The dose response curves in Figure 3 demonstrate IC 50 's in the micromolar range. It should be noted that 0% inhibition (100% activity) was not reached in all cases due to assay background fluorescence.

Prism via non-linear regression with a dose-response inhibition model (three parameters). Points represent mean of triplicates ± standard deviation (several standard deviations are too small to be discernable).

TCID (IC 50 = 138.0 μM ± 12.9), was ruled out as a possible scaffold due to its higher IC 50 value and potential toxicity 63 . While the most potent inhibitory compound was anacardic acid (IC 50 = 6.8 μM ± 1.0), its toxic liabilities may also prevent it from further development as an antiviral agent, whereas the two Aloe compounds (aloesin IC 50 = 38.9 μM ± 8.6, aloeresin D IC 50 = 125.3 μM ± 24.5), have a more favorable safety and efficacy profile in humans 56 . The four hits were also pre-incubated with and without the enzyme in order to assess time-dependent inhibition (TDI) (see supporting information, Figure S5 ).

While a single inhibitor concentration is not conclusive, the data suggest that the compounds exhibit a moderate amount of TDI. Experiments involving multiple concentrations points will need to be carried out to further delineate the TDI potential of these compounds. In an effort to expand our knowledge as to the specific mode of action of these compounds, a molecular docking study was undertaken using the AutoDock Vina algorithm, v. 1.1. As seen in Figure 4 , all four inhibitors docked within the active site of M pro , near the catalytic dyad of Cys 145 and His 41, although with differing binding energies. Aloesin bound with the lowest predicted free energy, -7.5 kcal/mol, followed by aloeresin D at -6.8 kcal/mol, TCID at -5.8 kcal/mol, and anacardic acid at -5.6 kcal/mol. TCID, the smallest molecule, docked near the Cys 145 at subsite S1

( Figure 4D ). Both aloesin and anacardic acid are bound in extended conformations, occupying the entirety of the active site, including subsites S1, S1', S2, and S4 (Figure 4 A, B) . In contrast, aloeresin D ( Figure   4C ) is bound in the active site in a more sterically constrained conformation, with the vinylphenol ring hovering just above the glycosyl moiety, only occupying subsites S1 and S4. This correlates well with the IC 50 potencies, where aloeresin D was approximately 3-fold less potent than aloesin (Figure 3) , and may indicate that the vinylphenol group of aloeresin D sterically hinders binding in the active site and in fact decreases the affinity of the ligand for M pro . Removal and/or substitution of this group with smaller functional groups could result in more potent inhibitors that fit more snugly into the active site. In addition, removal of the vinylphenol ring of aloeresin D would likely change its Lipinski's rules of five parameters, decreasing the number of violations and improving its drugability. We also attempted to dock vitamin K, a natural product with structural similarity to anacardic acid, but did not obtain a binding pose that met the search criteria, likely due to the unsaturated, rigid hydrocarbon tail present in the vitamin K structure. While the Aloe compounds are not extremely potent inhibitors on their own, these results illustrate their potential as molecular scaffolds that can be further developed into more efficacious M pro inhibitors. Furthermore, the excellent safety profile and bioavailability of both aloesin and aloeresin D make it likely that minor structural modifications to improve affinity to M pro will not result in producing significant toxic liabilities. Given the limited number of validated chemical scaffolds currently available for M pro inhibitors, identification of these compounds further adds to the medicinal chemist's toolkit for SARS-CoV-2 antiviral drug design.

In conclusion, here we have identified two natural product compounds, aloesin and aloeresin D, as novel SARS-CoV-2 M pro inhibitors through screening of a high-content protease inhibitor library. Both of these compounds are safe in humans and have functional groups that are readily accessible for modification allowing them to serve as leads for M pro inhibitors. Anacardic acid and TCID performed well in our study but were both ruled out due to potential toxicity. Additionally, we have confirmed that SARS-CoV-2 M pro exhibits cooperative kinetics during catalysis, suggesting that the protein dimer interface may be an attractive target for allosteric inhibitors. Combined, these results advance our knowledge of structure-function relationships in M pro and offer new molecular scaffolds for inhibitor design.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 

Provisional Counts for Coronavirus Disease 2019 (COVID-19)

Johns Hopkins Coronavirus Resource Center

Will Africans take COVID-19 vaccination?

Measuring vaccination willingness in response to COVID-19 using a multi-criteria-decision making method

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

COVID-19 Breakthrough Infections and Transmission Risk: Real-World Data Analyses from Germany's Largest Public Health Department (Cologne). Vaccines (Basel)

Emergence of deadly severe acute respiratory syndrome coronavirus-2 during 2019-2020

Trials and tribulations: so many potential treatments, so few answers

Perspectives on SARS-CoV-2 Main Protease Inhibitors

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target

Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays

Naturally Available Flavonoid Aglycones as Potential Antiviral Drug Candidates against SARS-CoV-2

Discovery of Di-and Trihaloacetamides as Covalent SARS-CoV-2

Main Protease Inhibitors with High Target Specificity

Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease

The SARS-CoV-2 main protease as drug target

HIV Protease: Historical Perspective and Current Research

Past HIV-1 Medications and the Current Status of Combined Antiretroviral Therapy Options for HIV-1 Patients

New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials

Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C

Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Identification of lactoferrin-derived peptides as potential inhibitors against the main protease of SARS-CoV-2

Phenylethanoid glycosides as a possible COVID-19 protease inhibitor: a virtual screening approach

De novo design of novel protease inhibitor candidates in the treatment of SARS-CoV-2 using deep learning, docking, and molecular dynamic simulations

Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L

Molecular Dynamic Simulations & Pharmacokinetic Predictions of Some Methyl β-D-Galactopyranoside Analogs

SARS-CoV-2 M(pro): A Potential Target for Peptidomimetics and Small-Molecule Inhibitors

In silico analyses of major active constituents of Fingerroot (Boesenbergia rotunda) unveils inhibitory activities against SARS-CoV-2 main protease enzyme

Development of a simple and miniaturized sandwich-like fluorescence polarization assay for rapid screening of SARS-CoV-2 main protease inhibitors

Drug Repurposing Approach against Novel Coronavirus Disease (COVID-19) through Virtual Screening Targeting SARS-CoV-2 Main Protease

Repurposing of Some Natural Product Isolates as SARS-COV-2 Main Protease Inhibitors via In Vitro Cell Free and Cell-Based Antiviral Assessments and Molecular Modeling Approaches

Elucidating a relationship between conformational sampling and drug resistance in HIV-1 protease

Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors

Combating susceptibility to drug resistance: lessons from HIV-1 protease

Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors

Diversity-oriented synthesis as a tool for identifying new modulators of mitosis

Chemical probes and drug leads from advances in synthetic planning and methodology

Cheminformatics Tools for Analyzing and Designing Optimized Small-Molecule Collections and Libraries

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Improved designs for pET expression plasmids increase protein production yield in Escherichia coli

Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery

A new look at the statistical model identification

Natural Polyphenols Inhibit the Dimerization of the SARS-CoV-2 Main Protease: The Case of Fortunellin and Its Structural Analogs

Regulation of the Dimerization and Activity of SARS-CoV-2

Main Protease through Reversible Glutathionylation of Cysteine 300. mBio

Mechanism for controlling the dimer-monomer switch and coupling dimerization to catalysis of the severe acute respiratory syndrome coronavirus 3C-like protease

NMR Spectroscopy of the Main Protease of SARS-CoV-2 and Fragment-Based Screening Identify Three Protein Hotspots and an Antiviral Fragment

Comprehensive virtual screening of

k flavonoids reveals novel insights into allosteric inhibition of SARS-CoV-2 M(PRO). Sci Rep

Novel dynamic residue network analysis approaches to study allosteric modulation: SARS-CoV-2 M(pro) and its evolutionary mutations as a case study

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

Barbaloin in aloe species

Royal Botanical Gardens, Kew)

A double-blind trial of a celandin, aloevera and psyllium laxative preparation in adult patients with constipation

Wound healing. Oral and topical activity of Aloe vera

Tyrosinase inhibitory components from Aloe vera and their antiviral activity

Mushroom tyrosinase inhibition activity of some chromones

Anti-Inflammatory, Antinociceptive, and Antioxidant Properties of Anacardic Acid in Experimental Models

Development of potent and selective inhibitors targeting the papainlike protease of SARS-CoV-2

Biomonitoring of human exposures to chlorinated derivatives and structural analogs of bisphenol A

declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work

When the optical density of the bacterial culture reached an absorbance of 0.5 at 600 nm, the expression was induced by the addition of isopropyl β-d-1-thiogalactopyranoside (0.5 mM) (Alfa Aesar, Haverhill, MA), and the culture was allowed to grow for another 5 h at 37°C and 250 rpm. The bacterial cells were then pelleted by centrifugation (3,400  g; 40 min) and stored at -80°C until purification. After the thawing and the resuspension of the bacterial cell pellets in buffer A (50 mM Tris-HCl, 150 mM NaCl, pH 7.8 at 4°C), the cells were lysed on ice by sonication (50% power, 6 bursts of 30 s and 2 min resting time between bursts

) and eluted using an imidazole gradient. Fractions (5 µL) were analyzed for purity by SDS-PAGE on a 4-15% Mini-Protean TGX precast gel

After a 2-fold dilution in buffer A, the digestion reaction was purified using the HisTrap-HP column where the HRV-3C protease stayed bound to the matrix via its His tag. The flow-through fractions containing the no tag M pro were then collected and analyzed by SDS-PAGE

Identification of proteasome and caspase inhibitors targeting SARS-CoV-2 Mpro

Identification of SARS-CoV-2 3CL Protease Inhibitors by a

Quantitative High-Throughput Screening

GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease

Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases

PubChem Compound Summary for CID 167551, Anacardic acid

PubChem Compound Summary for CID 160190, Aloesin

PubChem Compound Summary for CID 14211225, Aloeresin D

The authors would like to gratefully acknowledge the invaluable assistance of Dr. Phil Reigan with helpful discussions and input. This work was supported by a faculty start-up grant generously provided by the University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA. It should be noted that the University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences had no editorial input on the preparation of this manuscript or the planning, excitation, or interpretation of the experimental data.